Impact of Evolving Evidence on Pharmacological Therapy for Alcohol‐Associated Hepatitis in Alberta: A Population‐Based Study of Practice Trends and MELD ‐Stratified Effectiveness of Corticosteroids
Alimentary Pharmacology & Therapeutics · 2026
DOI: 10.1111/apt.70517 ↗At a glance
Journal article in Alimentary Pharmacology & Therapeutics, 2026. Written by Abdel-Aziz Shaheen and 3 co-authors. Institution: Division of Gastroenterology and Hepatology, Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada. Major MEDLINE topics: Pentoxifylline, Adrenal Cortex Hormones, Hepatitis, Alcoholic. 33 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: CIHR, Canadian Institutes of Health Research.
Abstract (original language)
Background and Aims Randomised trials such as the STOPAH trial questioned the efficacy of pentoxifylline (PTX) and provided mixed evidence for corticosteroids (CS) in alcohol‐associated hepatitis (AH). We aimed to assess temporal trends in the use of PTX and CS in Alberta and to evaluate the real‐world effectiveness of CS using a target trial emulation approach. Approach and Results We conducted a population‐based cohort study using linked administrative, laboratory and pharmaceutical data from Alberta, Canada. Adults hospitalised with AH between 2012 and 2023 who met National Institute on Alcohol Abuse and Alcoholism (NIAAA) criteria were included. Joinpoint regression evaluated changes in medication use and mortality trends. A sequence of emulated target trials estimated the effect of initiating CS within 7 days on 30‐ and 90‐day mortality. Among 2706 admissions (2138 patients), PTX use declined sharply after 2014 and was nearly absent after 2016. CS use increased modestly during the same period. Thirty‐day mortality decreased gradually after 2016, while 90‐day mortality remained stable. In 1365 patients with MELD ≥ 20, CS use was associated with a non‐significant 2% absolute reduction in 30‐day mortality (hazard ratio, 0.86; 95% CI, 0.73–1.03), with no effect at 90 days. No benefit was observed in patients with MELD > 35. Conclusions RCT evidence led to a rapid reversal in PTX prescribing prior to formal guideline updates. Real‐world data support a modest short‐term benefit of CS and illustrate the potential of target trial emulation to assess treatment effectiveness in specific groups of patients.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Division of Gastroenterology and Hepatology, Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
- Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
- Alberta Health Services, Calgary Health Zone, Calgary, Alberta, Canada.
- Division of Gastroenterology, Liver Unit, University of Alberta, Edmonton, Alberta, Canada.
Funding
- CIHR
- Canadian Institutes of Health Research
Cite
APA
Shaheen, A. A., Wang, M., Tkachuk, B., & Abraldes, J. G. (2026). Impact of Evolving Evidence on Pharmacological Therapy for Alcohol‐Associated Hepatitis in Alberta: A Population‐Based Study of Practice Trends and MELD ‐Stratified Effectiveness of Corticosteroids. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70517
Vancouver
Shaheen AA, Wang M, Tkachuk B, Abraldes JG. Impact of Evolving Evidence on Pharmacological Therapy for Alcohol‐Associated Hepatitis in Alberta: A Population‐Based Study of Practice Trends and MELD ‐Stratified Effectiveness of Corticosteroids. Alimentary Pharmacology & Therapeutics. 2026. doi:10.1111/apt.70517
BibTeX
@article{Shaheen2026,
author = {Shaheen, Abdel-Aziz and Wang, Meng and Tkachuk, Bryce and Abraldes, Juan G},
title = {Impact of Evolving Evidence on Pharmacological Therapy for Alcohol‐Associated Hepatitis in Alberta: A Population‐Based Study of Practice Trends and MELD ‐Stratified Effectiveness of Corticosteroids},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2026},
doi = {10.1111/apt.70517}
}
EUVIMED